At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
iLux 2020 Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
iLux Treatment for Meibomian Gland Dysfunction (MGD)
In Brief
A clinical study evaluating iLux 2020 System for Evaporative Dry Eye. Completed, enrolled 30 participants across 3 sites.
Detailed Summary
The purpose of this study is to assess changes in meibomian gland function and evaporative dry eye symptoms after treatment with the iLux medical device.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEvaporative Dry Eye
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartDec 2015
Primary CompletionFeb 2016
First PostedFeb 2017
TodayJul 2026
First PostedFeb 16, 2017
Enrollment StartDec 7, 2015
Primary CompletionFeb 18, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.4 years ago
Interventions
iLux 2020 Systemdevice
Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands